In pediatrics, a phase 1/2 clinical trial open in Europe and some U.S. centers is currently recruiting MLL-r infant ALL and FLT3-mutant AML patients to receive midostaurin as a single agent, with a primary outcome of determining the maximally tolerated dose (MTD). Here, FLT3 is linked to acute myeloid leukemia.